Evaluation of Patient Reported Satisfaction and Clinical Efficacy of Insulin Glargine 300 U/mL Versus 100 U/mL in Patients With Type 1 Diabetes Using Flash Glucose Monitoring System

Background and Aims: To analyze patient-reported satisfaction and clinical effectiveness of concentrated insulin glargine 300 U/mL (Gla-300) among patients with type 1 diabetes (T1D) using a flash glucose monitoring (FGM) system. Methods: This comparative study was conducted among 86 patients with T1D (aged 14-40 years), who were treated with Glargine 100 U/mL (Gla-100) and switched to Gla-300 at day 1 (baseline). The following data were collected from each patient: demographic information, clinical parameters, and glycemic control markers. All patients completed the Diabetes Treatment Satisfaction Questionnaire (Arabic version), first at baseline and then after 12 weeks. A comparison was done for all the data recorded at baseline (on Gla-100) and after 12 weeks (on Gla-300) and subjected to analysis. Results: Compared to patients treated with Gla-100, significant improvements were observed in the Gla-300 group, in terms of the ambulatory glucose profile (AGP) markers, such as percentage of time spent within the target range of the glucose levels (70-180 mg/dL) (P = .037), percentage which fell below the target (<70 mg/dL) (P = .027), and percentage of time spent (<54 mg/dL) (P = .043). Compared to Gla-100, patients treated with Gla-300 experienced significant improvements in the current treatment satisfactions (P = .047), convenient finding treatment recently (P = .034), and flexible finding treatment recently (P = .041), recommend the current treatment (P = .042) and satisfied to continue the current treatment (P = .035). Conclusion: Compared to the patients on Gla-100, patients treated with Gla-300 exhibited significant improvements in the AGP markers and degree of treatment satisfaction.

• Publication year

  2022

• Venue

  Clinical Medicine Insights: Endocrinology and Diabetes

• Publication date

  2022-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/11795514221098415PMID 35601879PMCID 9121452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Insulin Glargine 300 U/mL versus Glargine 100 U/mL on Glycemic Control and Hypoglycemic Events in East Asian Patients with Type 2 Diabetes: A Patient-level Meta-Analysis of Phase 3 Studies.

  2021cited by this paper
• Current and future therapies for type 1 diabetes

  2021cited by this paper
• Type 1 diabetes in an adolescent with social problems and mental disorders – case report

  2021cited by this paper
• Effectiveness of the freestyle libre 2 flash glucose monitoring system on diabetes-self-management practices and glycemic parameters among patients with type 1 diabetes using insulin pump.

  2021cited by this paper
• The ongoing evolution of basal insulin therapy over 100 years and its promise for the future

  2021cited by this paper
• Insulin Glargine 300 Units/mL Effectiveness in Patients with T2DM Uncontrolled by Basal Insulin in Real-Life Settings in the Czech Republic

  2020cited by this paper
• Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

  2020cited by this paper
• Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025

  2020cited by this paper
• Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

  2019cited by this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

  2019cited by this paper
• Diabetes Mellitus Type 1 In Children

  2019cited by this paper
• Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature

  2018cited by this paper
• Type 1 Diabetes Mellitus in Saudi Arabia: A Soaring Epidemic

  2018cited by this paper
• Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

  2017cited by this paper
• Comparison of Insulin Glargine 300 U / mL and 100 U / mL in Adults With Type 1 Diabetes : Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

  2017cited by this paper
• New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

  2016cited by this paper
• New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

  2016cited by this paper
• Basal insulin regime change from Lantus to Toujeo resulted in fewer hypoglycaemic episodes in a 28-year-old man with diabetes mellitus

  2016cited by this paper
• Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

  2016cited by this paper
• Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature.

  2016cited by this paper
• Efficacy of Insulin Pump Therapy on Diabetes Treatment Satisfaction and Glycemic Control Among Patients with Type 1 Diabetes Mellitus in Saudi Arabia: A Prospective Study

  2015cited by this paper
• Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

  2015cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014cited by this paper
• Clinical utility of insulin and insulin analogs

  2013cited by this paper
• Diabetes Treatment Satisfaction Questionnaire - an Arabic adaptation for Qatar.

  2013cited by this paper
• Patient satisfaction with diabetes care.

  2005cited by this paper
• Type 1 diabetes

  2002cited by this paper

• No citing papers are available for this paper.